Investigational drug · Phase 2
BBT002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BBT002"
First trial start
2026
Mar 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBT002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Largest trials
Live from ClinicalTrials.gov: studies naming "BBT002" as an intervention, largest first.
- A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)Pivotal-lookingRecruiting
Bambusa TherapeuticsIndustry
NCT06944925 · 286 participants (planned) · Start May 8, 2025 · Primary completion Jan 31, 2027
Drug: BBT002; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Bowling Green, Kentucky; Owensboro, Kentucky; New York, New York · 14 sites in all
Bambusa TherapeuticsIndustry
NCT07288554 · 68 participants (planned) · Start Sep 5, 2025 · Primary completion Dec 31, 2026
Drug: BBT002; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Hefei, China; Guangzhou, China; Jiangmen, China · 11 sites in all
Bambusa TherapeuticsIndustry
NCT07436949 · 64 participants (planned) · Start Mar 2, 2026 · Primary completion Dec 31, 2027
Drug: BBT002; Placebo · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Beijing, China; Guangzhou, China; Changsha, China · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.